Clinical Trial Update: A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of nivolumab plus intrapleural talimogene laherparepvec for malignant pleural effusion has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lung Cancer
• Malignant Pleural Effusion

Drugs mentioned

• Talimogene laherparepvec (talimogene laherparepvec)
• nivolumab (nivolumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Malignant Pleural Effusion, Stage IV Metastatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-04-20